With a wide range of viral and bacterial targets, you have access to a comprehensive menu of real-time PCR and sequencing assays for pathogen detection and monitoring. Viracor’s multiple-target, dual gene assays, an approach we adopted early in the transition to molecular diagnostics, are designed to eliminate false negative results or under-quantification.
Vaccine immunogenicity assays are needed to assess the safety and efficacy of the candidate vaccine, by measuring humoral and cellular immune responses, in an effort to correlate with immunity.
There are many complexities that make cell and gene therapy development challenging. It is crucial the new gene reaches the correct cell without causing an unintended immune response.
Chimeric antigen receptor (CAR) T-cell therapy - Adoptive cell therapies like CAR-T involve collection of immune cells from a patient followed by ex vivo manipulation and/or expansion and reinfusion, and are the foundations of immuno-oncology today after showing success in the treatment of hematologic malignancies.
Oncolytic viruses constitute a promising new therapeutic approach for treatment of cancer. These viruses selectively kill tumor cells without harming normal ones; with the added bonus of stimulating the patient’s immune response.
Viracor was among the first commercial labs to offer specialized allergy and immunology testing options using ImmunoCAP® and allergen-specific IgE enzyme immunoassays as the primary testing modes. Using high throughput instrumentation with high antigen binding capacity and minimal non-specific binding with high total IgE, Viracor offers you an unparalleled selection of thousands of allergy tests. Viracor manufactures nearly 200 unique discs for allergens not otherwise commercially available, and has the ability to create custom allergy panels to assist your studies. Commonly performed assays include allergen-specific IgE, IgG and IgG4 testing, tryptase and Eosinophil Cationic Protein (ECP).
Connect With Us